A Study of the Safety and Efficacy of CNTO 148 (Golimumab) in Children With Juvenile Idiopathic Arthritis (JIA) and Multiple Joint Involvement Who Have Poor Response to Methotrexate (GO KIDS)

NCT01230827 · clinicaltrials.gov ↗

PHASE3

Phase

TERMINATED

Status

173

Enrollment

INDUSTRY

Sponsor class

Stopped Trial has failed to meet primary - and major secondary endpoints

Conditions

Juvenile Idiopathic Arthritis

Interventions

DRUG: CNTO 148 (Golimumab)
DRUG: Placebo
DRUG: Methotrexate

Sponsor

Janssen Research & Development, LLC

Collaborators

[object Object]